{
    "title": "Eli Lilly profit beat helps ease investor concerns over growth",
    "url": "https://www.dailymail.co.uk/wires/reuters/article-7947139/Eli-Lilly-profit-beats-estimates-strong-Trulicity-sales.html",
    "date": "2020-01-30",
    "keywords": [
        "trulicity",
        "drug",
        "treatment",
        "competition",
        "growth",
        "company",
        "joseph",
        "taltz",
        "quarter",
        "analyst",
        "officer",
        "portfolio",
        "share",
        "cancer",
        "acquisition",
        "revenue",
        "jan",
        "fourthquarter",
        "profit",
        "thursday",
        "demand",
        "psoriasis",
        "investor",
        "impact",
        "accounting",
        "fifth",
        "launch",
        "pill",
        "rybelsus",
        "year",
        "aversion",
        "glp1",
        "class",
        "entry",
        "therapy",
        "joshua",
        "smiley",
        "conference",
        "call",
        "indianapolis",
        "drugmaker",
        "spree",
        "dysfunction",
        "market",
        "relative",
        "pricing",
        "focus",
        "navin",
        "jacob",
        "lung",
        "purchase",
        "trial",
        "course",
        "reward",
        "part",
        "future",
        "daniel",
        "skovronsky",
        "month",
        "deal",
        "executive",
        "david",
        "oncology",
        "lot",
        "runway",
        "disease",
        "specialist",
        "dermira",
        "inc",
        "estimate",
        "reporting",
        "sibi",
        "bengaluru",
        "carl",
        "york",
        "editing",
        "koyyur",
        "bill",
        "berkrot"
    ],
    "category": [
        "wires",
        "reuters"
    ]
}